Dale A. Sander - Aug 26, 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
CFO and Chief Corp. Deve. Off.
Signature
/s/ Dale A. Sander
Stock symbol
HUMA
Transactions as of
Aug 26, 2021
Transactions value $
$0
Form type
4
Date filed
8/27/2021, 04:09 PM
Next filing
May 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award +39.4K 39.4K Aug 26, 2021 Common Stock 39.4K $2.56 Direct F1, F2
transaction HUMA Stock Options (right to buy) Award +17.1K 17.1K Aug 26, 2021 Common Stock 17.1K $6.54 Direct F1, F2
transaction HUMA Stock Options (right to buy) Award +1.58K 1.58K Aug 26, 2021 Common Stock 1.58K $10.28 Direct F2, F3
transaction HUMA Stock Options (right to buy) Award +184K 184K Aug 26, 2021 Common Stock 184K $10.28 Direct F2, F4
transaction HUMA Stock Options (right to buy) Award +210K 210K Aug 26, 2021 Common Stock 210K $10.28 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options are fully vested and exercisable.
F2 On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
F3 Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
F4 Options vest annually in three equal installments on 11/09/2021, 11/09/2022, and 11/09/2023.
F5 Options vest annually in three equal installments on 05/14/2022, 05/14/2023, and 05/14/2024.